DOCSLIB.ORG

Complete Thesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Complete Thesis University of Groningen Genotyping and phenotyping epilepsies of childhood Vlaskamp, Danique IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2018 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Vlaskamp, D. (2018). Genotyping and phenotyping epilepsies of childhood. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 02-10-2021 Genotyping and phenotyping epilepsies of childhood Danique Vlaskamp 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 1 Layout Douwe Oppewal Cover design Christien Rondaan Printed by Ipskamp Printing, Enschede, the Netherlands ISBN 978-94-034-1144-6 (printed version) 978-94-034-1143-9 (e-book) © Copyright 2018 D.R.M. Vlaskamp, Groningen, the Netherlands All rights reserved. No part of this publication may be reproduced or transmitted in any forms or by any means, without prior written permission of the author. This research was funded by the Junior Scientifi c Masterclass. Unrestricted travel grants were received from the Dutch Society of Child Neurology, Jo Kolk Foundation (VVAO), the Research School of Behavioural and Cognitive Neurosciences (BCN). Conference attendances were fi nancially supported by the BCN. Printing of this thesis was fi nancially supported by the the University of Groningen and the BCN. 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 2 Genotyping and phenotyping epilepsies of childhood Proefschrift ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 05 december 2018 om 14.30 uur door Danique Rienke Maria Vlaskamp geboren op 15 mei 1991 te Raalte 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 3 Promotores Prof. dr. C.M.A. van Ravenswaaij-Arts Prof. dr. O.F. Brouwer Copromotores Dr. P.M.C. Callenbach Dr. P. Rump Beoordelingscommissie Prof. dr. V.V.A.M. Knoers Prof. dr. H.P.H. Kremer Prof. dr. K.P.J. Braun 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 4 COVER The tree on the cover of this thesis symbolizes the relationship between the genotype and the phenotype of epilepsies of childhood. The beautiful tree has deeply anchored, widely spreading roots (genotype) that grow a new flowering tree with a unique pattern of branches, leaves and blossoms (phenotype). Painted by Christien Rondaan 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 5 6 Paranimfen Nienke te Grootenhuis Wieke Eggink 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 6 7 CONTENTS Chapter 1 Introduction 9 PART I - THE YIELD OF GENETIC TESTING Chapter 2 Copy number variation in a hospital-based cohort of children with epilepsy 27 Published as: Epilepsia Open. 2017; 2: 244–254. Chapter 3 Empowerment and anxiety of patients and parents 49 during genetic counseling for epilepsy Manuscript ready to submit PART II - GENOTYPE-PHENOTYPE STUDIES Chapter 4 SYNGAP1 encephalopathy: a distinctive generalized 71 developmental and epileptic encephalopathy Accepted for publication in Neurology Chapter 5 Genotype-phenotype correlation of 248 individuals with 95 GRIN2A-related disorders identifies two distinct phenotypic subgroups associated with different classes of variants, protein domains and functional consequences Accepted for publication in Brain Chapter 6 Schizophrenia is a later-onset feature of PCDH19 Girls Clustering Epilepsy 123 Revised version under review Chapter 7 Haploinsufficiency of the STX1B gene is associated with 145 myoclonic astatic epilepsy Published as: European Journal of Paediatric Neurology. 2016; 20: 489-492 Chapter 8 PRRT2-related phenotypes in patients with a 16p11.2 deletion 157 Published as: European Journal of Medical Genetics. 2018, in press. Chapter 9 Positive effect of sodium channel blocking anti-epileptic 177 drugs on neonatal infantile epilepsy due to a SCN2A mutation Translated from the Dutch paper published as: Epilepsie. 2017; Periodiek voor Professionals 15, nr.3 Chapter 10 General discussion and a proposal for a diagnostic algorithm 185 for genetic testing for epilepsy Chapter 11 Nederlandse samenvatting 201 Dankwoord 208 Curriculum vitae 213 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 7 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 8 9 Chapter 1 Introduction 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 9 10 CHAPTER 1 I am about to discuss the disease called “sacred.” It is not, in my opinion, any more divine or more sacred than any other diseases, but has a natural cause… Its origin, like that of other diseases, lies in heredity... The fact is that the cause of this affection is... the brain... My own view is that those who first attributed a sacred character to this malady were like the magicians, purifiers, charlatans, and quacks of our own day... So that there is no need to put the disease in a special class and to consider it more divine than the others... Each has a nature and a power of its own; none is hopeless or incapable of treatment.1 Hippocrates, 460–370 BC, on epilepsy Hippocrates was revolutionary for his time in arguing that the origin of epilepsy lies in ‘heredity’. Although hereditary does not always equal genetic, we now have robust evidence that genetic variants can cause or contribute to epilepsy. However, we still have a long way to go to fully understand the intriguing role of genetics in epilepsy. To comprehend the current challenges in epilepsy genetics addressed in this thesis, it is helpful to learn more about epilepsy phenotyping and genotyping. Whereas epilepsy phenotyping concentrates on describing the clinical presentation, epilepsy genotyping focuses on identifying the underlying genetic cause. Integration of information on epilepsy phenotype and genotype is important in clinical practice and research settings in order to find new genes and risk factors for epilepsy, to better understand the disease and its presentation and to improve its management and outcome. 525699-L-sub01-bw-Vlaskamp Processed on: 29-10-2018 PDF page: 10 INTRODUCTION 11 EPILEPSY PHENOTYPING 1 An epileptic seizure is defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.2 Seizures can be provoked by acute disturbances in the body, such as hypoglycemia or acute infection, or can occur unprovoked. Patients are diagnosed with epilepsy if they present with any of the following three conditions: 1. at least two unprovoked seizures occurring >24 hours apart, 2. one unprovoked (or reflex) seizure and a probability of further seizures in the next 10 years similar to the general recurrence risk after two unprovoked seizures (at least 60%), or 3. a diagnosis of an epilepsy syndrome.3 Epilepsy is diagnosed in 41-87 children per 100,000 children each year.4 Epilepsy is not a single disease entity, but should be considered as a group of disorders. Its presentation, etiology, management and prognosis can vary significantly for the different epilepsies. Epilepsy therefore warrants further classification for clinical and research purposes. The International League Against Epilepsy (ILAE) has made several classification guidelines.5–11 In the most recent guideline from 2017, they recommended classifying epilepsy at three consecutive levels: 1. seizure type, 2. epilepsy type, and 3. epilepsy syndrome.12 The flowchart in Figure 1 demonstrates how to classify epilepsies using this three-step method. Depending on the availability of clinical information, epilepsy can be classified up to level 1, 2 or 3. 1. Seizure type. Epileptic seizures should be classified based on their onset as focal, generalized or unknown.12,13 Epilepsy is a disorder involving neuronal networks and all seizures are hypothesized to occur somewhere within a network.14,15 Focal seizures are limited to networks within one hemisphere, while generalized seizures rapidly engage bilaterally distributed networks.16 Both clinical and electroencephalogram (EEG) data can help to distinguish focal and generalized seizures. If more detailed clinical information on the seizures is available, they can be further classified based on the level of awareness (for focal seizures only) and by describing their first feature.12,13 Focal seizures can evolve to bilateral tonic-clonic seizures (previously called ‘secondary generalized seizures’).12,13,17 2. Epilepsy type. Since individuals can have both focal and generalized seizures, a second level of classification has been introduced: epilepsy type. Epilepsy type can be focal, generalized or combined generalized and focal.12 3. Epilepsy syndrome. To diagnose the epilepsy syndrome, one should also consider the setting in which seizures occur. This setting includes the patient’s gender, age at seizure onset, developmental course, family history, and results from additional investigations such as EEG and imaging.
Load more

Recommended publications
  • Gene Nomenclature System for Rice
    Rice (2008) 1:72–84 DOI 10.1007/s12284-008-9004-9 Gene Nomenclature System for Rice Susan R. McCouch & CGSNL (Committee on Gene Symbolization, Nomenclature and Linkage, Rice Genetics Cooperative) Received: 11 April 2008 /Accepted: 3 June 2008 /Published online: 15 August 2008 # The Author(s) 2008 Abstract The Committee on Gene Symbolization, Nomen- protein sequence information that have been annotated and clature and Linkage (CGSNL) of the Rice Genetics Cooper- mapped on the sequenced genome assemblies, as well as ative has revised the gene nomenclature system for rice those determined by biochemical characterization and/or (Oryza) to take advantage of the completion of the rice phenotype characterization by way of forward genetics. With genome sequence and the emergence of new methods for these revisions, we enhance the potential for structural, detecting, characterizing, and describing genes in the functional, and evolutionary comparisons across organisms biological community. This paper outlines a set of standard and seek to harmonize the rice gene nomenclature system procedures for describing genes based on DNA, RNA, and with that of other model organisms. Newly identified rice genes can now be registered on-line at http://shigen.lab.nig. ac.jp/rice/oryzabase_submission/gene_nomenclature/. The current ex-officio member list below is correct as of the date of this galley proof. The current ex-officio members of CGSNL (The Keywords Oryza sativa . Genome sequencing . Committee on Gene Symbolization, Nomenclature and Linkage) are: Gene symbolization Atsushi Yoshimura from the Faculty of Agriculture, Kyushu University, Fukuoka, 812-8581, Japan, email: [email protected] Guozhen Liu from the Beijing Institute of Genomics of the Chinese Introduction Academy of Sciences, Beijing, People’s Republic of China, email: [email protected] The biological community is moving towards a universal Yasuo Nagato from the Graduate School of Agricultural and Life system for the naming of genes.
    [Show full text]
  • Systematic Review of the Genetics of Sudden Unexpected Death in Epilepsy: Potential Overlap with Sudden Cardiac Death and Arrhythmia-Related Genes C
    SYSTEMATIC REVIEW AND META-ANALYSIS Systematic Review of the Genetics of Sudden Unexpected Death in Epilepsy: Potential Overlap With Sudden Cardiac Death and Arrhythmia-Related Genes C. Anwar A. Chahal, MBChB; Mohammad N. Salloum, MD; Fares Alahdab, MD; Joseph A. Gottwald, PharmD; David J. Tester, BS; Lucman A. Anwer, MD; Elson L. So, MD; Mohammad Hassan Murad, MD, MPH; Erik K. St Louis, MD, MS; Michael J. Ackerman, MD, PhD; Virend K. Somers, MD, PhD Background-—Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related death. SUDEP shares many features with sudden cardiac death and sudden unexplained death in the young and may have a similar genetic contribution. We aim to systematically review the literature on the genetics of SUDEP. Methods and Results-—PubMed, MEDLINE Epub Ahead of Print, Ovid Medline In-Process & Other Non-Indexed Citations, MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Scopus were searched through April 4, 2017. English language human studies analyzing SUDEP for known sudden death, ion channel and arrhythmia-related pathogenic variants, novel variant discovery, and copy number variant analyses were included. Aggregate descriptive statistics were generated; data were insufficient for meta- analysis. A total of 8 studies with 161 unique individuals were included; mean was age 29.0 (ÆSD 14.2) years; 61% males; ECG data were reported in 7.5% of cases; 50.7% were found prone and 58% of deaths were nocturnal. Cause included all types of epilepsy. Antemortem diagnosis of Dravet syndrome and autism (with duplication of chromosome 15) was associated with 11% and 9% of cases.
    [Show full text]
  • A Genetic Screen for Genes That Impact Peroxisomes in Drosophila Identifies
    bioRxiv preprint doi: https://doi.org/10.1101/704122; this version posted July 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. A genetic screen for genes that impact peroxisomes in Drosophila identifies candidate genes for human disease Hillary K. Graves1, Sharayu Jangam1, Kai Li Tan1, Antonella Pignata1, Elaine S. Seto1, Shinya Yamamoto1,2,3,4# and Michael F. Wangler1,3,4,# 1Department of Molecular and Human Genetics, Baylor College of Medicine (BCM), Houston, TX 77030, USA 2Department of Neuroscience, BCM, Houston, TX 77030, USA 3Program in Developmental Biology, BCM, Houston, TX 77030, USA 4Jan and Dan Duncan Neurological Research Institute, Texas Children Hospital, Houston, TX 77030, USA #Corresponding authors: SY ([email protected]), MFW ([email protected]) Keywords: Drosophila, peroxisomes, BRD4, fs(1)h bioRxiv preprint doi: https://doi.org/10.1101/704122; this version posted July 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Peroxisomes are sub-cellular organelles that are essential for proper function of eukaryotic cells. In addition to being the sites of a variety of oxidative reactions, they are crucial regulators of lipid metabolism. Peroxisome loss or dysfunction leads to multi- system diseases in humans that strongly affects the nervous system.
    [Show full text]
  • Indicators of the Molecular Pathogenesis of Virulent Newcastle
    www.nature.com/scientificreports OPEN Indicators of the molecular pathogenesis of virulent Newcastle disease virus in chickens revealed by transcriptomic profling of spleen Mohammad Rabiei1*, Wai Yee Low2, Yan Ren2, Mohamad Indro Cahyono3, Phuong Thi Kim Doan1,4, Indi Dharmayanti3, Eleonora Dal Grande1 & Farhid Hemmatzadeh1,2 Newcastle disease virus (NDV) has caused signifcant outbreaks in South-East Asia, particularly in Indonesia in recent years. Recently emerged genotype VII NDVs (NDV-GVII) have shifted their tropism from gastrointestinal/respiratory tropism to a lymphotropic virus, invading lymphoid organs including spleen and bursa of Fabricius to cause profound lymphoid depletion. In this study, we aimed to identify candidate genes and biological pathways that contribute to the disease caused by this velogenic NDV-GVII. A transcriptomic analysis based on RNA-Seq of spleen was performed in chickens challenged with NDV-GVII and a control group. In total, 6361 genes were diferentially expressed that included 3506 up-regulated genes and 2855 down-regulated genes. Real-Time PCR of ten selected genes validated the RNA-Seq results as the correlation between them is 0.98. Functional and network analysis of Diferentially Expressed Genes (DEGs) showed altered regulation of ElF2 signalling, mTOR signalling, proliferation of cells of the lymphoid system, signalling by Rho family GTPases and synaptogenesis signalling in spleen. We have also identifed modifed expression of IFIT5, PI3K, AGT and PLP1 genes in NDV-GVII infected chickens. Our fndings in activation of autophagy-mediated cell death, lymphotropic and synaptogenesis signalling pathways provide new insights into the molecular pathogenesis of this newly emerged NDV-GVII. Newcastle disease virus (NDV) has a worldwide distribution.
    [Show full text]
  • Identification of Common Gene Networks Responsive To
    Cancer Gene Therapy (2014) 21, 542–548 © 2014 Nature America, Inc. All rights reserved 0929-1903/14 www.nature.com/cgt ORIGINAL ARTICLE Identification of common gene networks responsive to radiotherapy in human cancer cells D-L Hou1, L Chen2, B Liu1, L-N Song1 and T Fang1 Identification of the genes that are differentially expressed between radiosensitive and radioresistant cancers by global gene analysis may help to elucidate the mechanisms underlying tumor radioresistance and improve the efficacy of radiotherapy. An integrated analysis was conducted using publicly available GEO datasets to detect differentially expressed genes (DEGs) between cancer cells exhibiting radioresistance and cancer cells exhibiting radiosensitivity. Gene Ontology (GO) enrichment analyses, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein–protein interaction (PPI) networks analysis were also performed. Five GEO datasets including 16 samples of radiosensitive cancers and radioresistant cancers were obtained. A total of 688 DEGs across these studies were identified, of which 374 were upregulated and 314 were downregulated in radioresistant cancer cell. The most significantly enriched GO terms were regulation of transcription, DNA-dependent (GO: 0006355, P = 7.00E-09) for biological processes, while those for molecular functions was protein binding (GO: 0005515, P = 1.01E-28), and those for cellular component was cytoplasm (GO: 0005737, P = 2.81E-26). The most significantly enriched pathway in our KEGG analysis was Pathways in cancer (P = 4.20E-07). PPI network analysis showed that IFIH1 (Degree = 33) was selected as the most significant hub protein. This integrated analysis may help to predict responses to radiotherapy and may also provide insights into the development of individualized therapies and novel therapeutic targets.
    [Show full text]
  • The Prepattern Transcription Factor Irx3 Directs Nephron Segment Identity
    Downloaded from genesdev.cshlp.org on October 8, 2021 - Published by Cold Spring Harbor Laboratory Press The prepattern transcription factor Irx3 directs nephron segment identity Luca Reggiani,1 Daniela Raciti,1 Rannar Airik,2 Andreas Kispert,2 and André W. Brändli1,3 1Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, CH-8093 Zurich, Switzerland; 2Institute of Molecular Biology, Hannover Medical School, D-30625 Hannover, Germany The nephron, the basic structural and functional unit of the vertebrate kidney, is organized into discrete segments, which are composed of distinct renal epithelial cell types. Each cell type carries out highly specific physiological functions to regulate fluid balance, osmolarity, and metabolic waste excretion. To date, the genetic basis of regionalization of the nephron has remained largely unknown. Here we show that Irx3,a member of the Iroquois (Irx) gene family, acts as a master regulator of intermediate tubule fate. Comparative studies in Xenopus and mouse have identified Irx1, Irx2, and Irx3 as an evolutionary conserved subset of Irx genes, whose expression represents the earliest manifestation of intermediate compartment patterning in the developing vertebrate nephron discovered to date. Intermediate tubule progenitors will give rise to epithelia of Henle’s loop in mammals. Loss-of-function studies indicate that irx1 and irx2 are dispensable, whereas irx3 is necessary for intermediate tubule formation in Xenopus. Furthermore, we demonstrate that misexpression of irx3 is sufficient to direct ectopic development of intermediate tubules in the Xenopus mesoderm. Taken together, irx3 is the first gene known to be necessary and sufficient to specify nephron segment fate in vivo.
    [Show full text]
  • The Genetic Basis of Malformation of Cortical Development Syndromes: Primary Focus on Aicardi Syndrome
    The Genetic Basis of Malformation of Cortical Development Syndromes: Primary Focus on Aicardi Syndrome Thuong Thi Ha B. Sc, M. Bio Neurogenetics Research Group The University of Adelaide Thesis submitted for the degree of Doctor of Philosophy In Discipline of Genetics and Evolution School of Biological Sciences Faculty of Science The University of Adelaide June 2018 Table of Contents Abstract 6 Thesis Declaration 8 Acknowledgements 9 Publications 11 Abbreviations 12 CHAPTER I: Introduction 15 1.1 Overview of Malformations of Cortical Development (MCD) 15 1.2 Introduction into Aicardi Syndrome 16 1.3 Clinical Features of Aicardi Syndrome 20 1.3.1 Epidemiology 20 1.3.2 Clinical Diagnosis 21 1.3.3 Differential Diagnosis 23 1.3.4 Development & Prognosis 24 1.4 Treatment 28 1.5 Pathogenesis of Aicardi Syndrome 29 1.5.1 Prenatal or Intrauterine Disturbances 29 1.5.2 Genetic Predisposition 30 1.6 Hypothesis & Aims 41 1.6.1 Hypothesis 41 1.6.2 Research Aims 41 1.7 Expected Outcomes 42 CHAPTER II: Materials & Methods 43 2.1 Study Design 43 2.1.1 Cohort of Study 44 2.1.2 Inheritance-based Strategy 45 1 2.1.3 Ethics for human and animals 46 2.2 Computational Methods 46 2.2.1 Pre-Processing Raw Reads 46 2.2.2 Sequencing Coverage 47 2.2.3 Variant Discovery 49 2.2.4 Annotating Variants 53 2.2.5 Evaluating Variants 55 2.3 Biological Methods 58 2.3.1 Cell Culture 58 2.3.2 Genomic DNA Sequencing 61 2.3.3 Plasmid cloning 69 2.3.4 RNA, whole exome & Whole Genome Sequencing 74 2.3.5 TOPFlash Assay 75 2.3.6 Western Blot 76 2.3.7 Morpholino Knockdown in Zebrafish 79 CHAPTER III: A mutation in COL4A2 causes autosomal dominant porencephaly with cataracts.
    [Show full text]
  • Highlights of the 'Gene Nomenclature Across Species' Meeting
    MEETING REPORT Highlights of the ‘Gene Nomenclature Across Species’ Meeting Elspeth A. Bruford* Project Coordinator, HUGO Gene Nomenclature Committee (HGNC), EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, UK *Correspondence to: E-mail: [email protected] Date received (in revised form): 24th February, 2010 Abstract The first ‘Gene Nomenclature Across Species’ meeting was held on 12th and 13th October 2009, at the Møller Centre in Cambridge, UK. This meeting, organised and hosted by the HUGO Gene Nomenclature Committee (HGNC), brought together invited experts from the fields of gene nomenclature, phylogenetics and genome assembly and annotation. The central aim of the meeting was to discuss the issues of coordinating gene naming across vertebrates, culminating in the publication of recommendations for assigning nomenclature to genes across multiple species. Meeting summary coorganiser of the meeting, kicked off by discussing The meeting began with a welcome and outline of the current work of the HGNC, ‘An Essential the agenda from Elspeth Bruford, one of the Resource for the Human Genome’. Matt outlined meeting organisers and the group coordinator for the roles of the HGNC, including a summary of the HUGO Gene Nomenclature Committee the process of symbol assignment, and its current (HGNC). HGNC has been based at the European efforts in coordinating gene naming across ver- Bioinformatics Institute (EBI) at Hinxton, UK, tebrates. He also highlighted instances where the since 2007. Since its inception in 1979, the lack of approved gene nomenclature for most mam- HGNC has been assigning gene symbols and malian genomes has resulted in valuable published names to all human genes, including pseudogenes data for these species being absent or confused in and non-coding RNAs.
    [Show full text]
  • Abundant and Dynamically Expressed Mirnas, Pirnas, and Other Small Rnas in the Vertebrate Xenopus Tropicalis
    Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Abundant and dynamically expressed miRNAs, piRNAs, and other small RNAs in the vertebrate Xenopus tropicalis Javier Armisen,1,2,3 Michael J. Gilchrist,1,3 Anna Wilczynska,2 Nancy Standart,2 and Eric A. Miska1,2,4 1Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, The Henry Wellcome Building of Cancer and Developmental Biology, Cambridge CB2 1QN, United Kingdom; 2Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, United Kingdom Small regulatory RNAs have recently emerged as key regulators of eukaryotic gene expression. Here we used high- throughput sequencing to determine small RNA populations in the germline and soma of the African clawed frog Xenopus tropicalis. We identified a number of miRNAs that were expressed in the female germline. miRNA expression profiling revealed that miR-202-5p is an oocyte-enriched miRNA. We identified two novel miRNAs that were expressed in the soma. In addition, we sequenced large numbers of Piwi-associated RNAs (piRNAs) and other endogenous small RNAs, likely representing endogenous siRNAs (endo-siRNAs). Of these, only piRNAs were restricted to the germline, suggesting that endo-siRNAs are an abundant class of small RNAs in the vertebrate soma. In the germline, both endogenous small RNAs and piRNAs mapped to many high copy number loci. Furthermore, endogenous small RNAs mapped to the same specific subsets of repetitive elements in both the soma and the germline, suggesting that these RNAs might act to silence repetitive elements in both compartments. Data presented here suggest a conserved role for miRNAs in the vertebrate germline.
    [Show full text]
  • Downloaded from the CAVA Integration with Data Generated by Pre-NGS Methods Webpage [19]
    Münz et al. Genome Medicine (2015) 7:76 DOI 10.1186/s13073-015-0195-6 METHOD Open Access CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting Márton Münz1†, Elise Ruark2†, Anthony Renwick2, Emma Ramsay2, Matthew Clarke2, Shazia Mahamdallie2,3, Victoria Cloke3, Sheila Seal2,3, Ann Strydom2,3, Gerton Lunter1 and Nazneen Rahman2,3,4* Abstract Background: Next-generation sequencing (NGS) offers unprecedented opportunities to expand clinical genomics. It also presents challenges with respect to integration with data from other sequencing methods and historical data. Provision of consistent, clinically applicable variant annotation of NGS data has proved difficult, particularly of indels, an important variant class in clinical genomics. Annotation in relation to a reference genome sequence, the DNA strand of coding transcripts and potential alternative variant representations has not been well addressed. Here we present tools that address these challenges to provide rapid, standardized, clinically appropriate annotation of NGS data in line with existing clinical standards. Methods: We developed a clinical sequencing nomenclature (CSN), a fixed variant annotation consistent with the principles of the Human Genome Variation Society (HGVS) guidelines, optimized for automated variant annotation of NGS data. To deliver high-throughput CSN annotation we created CAVA (Clinical Annotation of VAriants), a fast, lightweight tool designed for easy incorporation into NGS pipelines. CAVA allows transcript specification, appropriately accommodates the strand of a gene transcript and flags variants with alternative annotations to facilitate clinical interpretation and comparison with other datasets. We evaluated CAVA in exome data and a clinical BRCA1/BRCA2 gene testing pipeline.
    [Show full text]
  • The Human Gamma-Glutamyltransferase Gene Family
    Hum Genet (2008) 123:321–332 DOI 10.1007/s00439-008-0487-7 REVIEW The human gamma-glutamyltransferase gene family Nora Heisterkamp · John GroVen · David Warburton · Tam P. Sneddon Received: 9 November 2007 / Accepted: 6 March 2008 / Published online: 21 March 2008 © Springer-Verlag 2008 Abstract Assays for gamma-glutamyl transferase related genes or sequences. These sequences were given (GGT1, EC 2.3.2.2) activity in blood are widely used in a multiple diVerent names, leading to inconsistencies and clinical setting to measure tissue damage. The well-charac- confusion. Here we systematically evaluated all human terized GGT1 is an extracellular enzyme that is anchored to sequences related to GGT1 using genomic and cDNA data- the plasma membrane of cells. There, it hydrolyzes and base searches and identiWed thirteen genes belonging to the transfers -glutamyl moieties from glutathione and other extended GGT family, of which at least six appear to be -glutamyl compounds to acceptors. As such, it has a critical active. In collaboration with the HUGO Gene Nomencla- function in the metabolism of glutathione and in the con- ture Committee (HGNC) we have designated possible version of the leukotriene LTC4 to LTD4. GGT deWciency active genes with nucleotide or amino acid sequence simi- in man is rare and for the few patients reported to date, larity to GGT1, as GGT5 (formerly GGL, GGTLA1/GGT- mutations in GGT1 have not been described. These patients rel), GGT6 (formerly rat ggt6 homologue) and GGT7 (for- do secrete glutathione in urine and fail to metabolize LTC4. merly GGTL3, GGT4). Two loci have the potential to Earlier pre-genome investigations had indicated that encode only the light chain portion of GGT and have now besides GGT1, the human genome contains additional been designated GGTLC1 (formerly GGTL6, GGTLA4) and GGTLC2.
    [Show full text]
  • Decision Support for Molecular Diagnostic Laboratories Using Interactive Biosoftware Alamut V1.2
    EuroGentest Unit 5 New technologies Decision support for molecular diagnostic laboratories using Interactive Biosoftware Alamut v1.2 November 2007- February 2008 Prepared by: NGRL Manchester As part of the activities of: EuroGentest Unit 5 Quality Management and Accreditation / Certification of Genetic Testing within the work package WP5.4. EuroGentest Project Co-ordinator: Professsor Jean-Jaques Cassiman K.U.Leuven Center for Human Genetics/ Centrum Menselijke Erfelijkheid Gasthuisberg O&N Herestraat 49 Box 602 3000 Leuven Belgium The views expressed in this document are those of the work package participants and do not necessarily reflect the policies of the institutions or companies they are affiliated to. © July 2008 Copyright EuroGentest Network of Excellence Project 2005 - EU Contract no. FP6-512148 Table of contents Summary ii Acknowledgements ii Introduction 1 Background 1 Description of tool 1 Evaluation 3 Aim 3 Methods 3 Results 5 User interface and usability 5 Data sources 5 Applicability to diagnostic testing 8 Validity and accuracy 8 Conclusions 15 Glossary 16 Appendix A Tested Gene Variants 18 i Summary Alamut is a decision-support software application developed by Interactive Biosoftware for mutation diagnostics in medical molecular genetics. It is a client- server application that integrates genetic information from different sources to describe variants using HGVS nomenclature and to help interpret their pathogenic status. We evaluated Alamut in four areas: its user interface and usability; the suitability of its data sources; its applicability to diagnostic testing; and its validity and accuracy. Laboratories found the software intuitive and easy to use, and well adapted to diagnostic testing. Over 400 variants from 14 genes were tested.
    [Show full text]